Opinion|Podcasts|November 1, 2024
Diagnostic Approach to CSU
Key Takeaways
- CSU diagnosis requires detailed patient history and symptom assessment, focusing on wheals, hives, and angioedema.
- The chronic and spontaneous nature of CSU complicates diagnosis due to symptom variability and lack of identifiable triggers.
Panelists discuss the clinical diagnosis of chronic spontaneous urticaria (CSU), outlining the necessary steps for assessment, including the evaluation of wheals, hives, and angioedema, while addressing how the chronic and spontaneous characteristics of the disease can complicate the diagnostic process.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Let’s talk about the diagnosis of CSU. What steps are involved with making a clinical diagnosis of CSU?
- Can you describe assessment for wheals, hives, angioedema, and any other pertinent symptoms?
- To what extent do the chronic and spontaneous nature of the disease impact the ability to make a diagnosis
Advertisement
Related to this article
Katherine Tuttle, MD, joins Brendon Neuen, MBBS, PhD, and Shikha Wadhwani, MD, MS, to unpack new FIND-CKD finerenone analyses from ASN 2026.
Jicheng Lv, MD, joins Brendon Neuen, MBBS, PhD, and Shikha Wadhwani, MD, MS, to discuss 2-year TELIGAN data for telitacicept in IgAN.
A PROTECT biomarker analysis shows sparsentan reduced urinary sCD163, BAFF, C5b-9, and IL-6 vs irbesartan through 110 weeks in IgA nephropathy.
Diana Isaacs, PharmD, and Natalie Bellini, DNP, review early MiniMed Vivera data on optional meal announcements and twiist's new type 2 diabetes clearance.
Real-world data in 1477 patients on dialysis show tenapanor reduced serum phosphate at 6 months with or without background phosphate binders.
Approval rests on the phase 3 AFFIRM trial, in which 56% of patients reached clinical remission at week 12 vs 30% with placebo.
Jean Elwing, MD, discusses what drove ralinepag's reduction in PAH clinical worsening in ADVANCE Outcomes and where the it could fit if approved.
Jean Elwing, MD, discusses a CHEST 2026 subgroup analysis showing ralinepag reduces clinical worsening in PAH even among patients with low-risk criteria.
Advertisement
Advertisement
Trending on HCPLive
1
Ralinepag's Benefit Spans Broad PAH Population, With Jean Elwing, MD
2
Sibeprenlimab Stabilizes eGFR Over 24 Months in IgA Nephropathy: VISIONARY
3
Retatrutide Lowers Albuminuria, Glomerular Pressure in Obesity and CKD
4
Ralinepag Cuts PAH Worsening in Low-Risk Patients, With Jean Elwing, MD
5